EUVIMEDEUVIMED entdecken
Crossref

Bridging the Gap: Efficacy of Low‐Dose Emicizumab in Haemophilia A With or Without Inhibitors

Gaurav Datta iD, Shailendra Prasad Verma, Swasti Sinha, Anil Kumar Tripathi, Rajesh Kashyap, Ruchira Mukherji, Raghuveer Punuru, Aritra Saha, Akshay Middinti, Rajkumar Maurya, Alpika Shukla, Rashmi Kushwaha und 1 weitere

Haemophilia · 2026

DOI: 10.1111/hae.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Gaurav Datta und 12 weiteren Autor:innen. Beteiligte Einrichtung: King George's Medical University, Lucknow, India. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Emicizumab has proven to be a turning point in the management of patients with Haemophilia A (HA). In resource‐limited settings, data on low‐dose emicizumab prophylaxis (LDEP) in HA patients are emerging.

Methods

Thirty‐seven patients previously on factor FVIII prophylaxis or bypassing agents (BPAs) received LDEP at a dose of 3‐mg/kg SC for 4 weeks, followed by 1.5‐mg/kg SC every 2 weeks. The primary objective was to assess the efficacy of LDEP measured in the form of reduction in annualised bleed rates (ABR), treated joint bleed and conversion of target joint to non‐target joint. The secondary objectives were to study the improvement in joint scores (HJHS and FISH score) and to assess quality of life.

Results

The median duration of LDEP was 15 months. On LDEP, the mean ABR was 0.41 ± 0.7 (median = 0; IQR: 0–0.6). Sixty‐seven percent of patients had zero bleeds, and 66% of target joints converted to non‐target joints. There was a significant improvement in HJHS, FISH and QoL in patients.

Conclusion

LDEP, although not optimal, remains an effective strategy in the prevention of bleeds, improvement of QOL and reduction of joint‐related disability in HA patients in resource‐constrained settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, Monoclonal, HumanizedAntibodies, BispecificHumansMaleQuality of LifeAdultTreatment OutcomeAdolescentFactor VIIIYoung AdultMiddle AgedHemorrhageChildFemale

Stichwörter der Autor:innen

emicizumabhaemophilia Alow‐dose emicizumab prophylaxisreal‐world study

Substanzen

Antibodies, Monoclonal, HumanizedemicizumabAntibodies, BispecificFactor VIII

Autor:innen und Institutionen

  • King George's Medical University, Lucknow, India.
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
  • Army Institute of Cardio-Thoracic Sciences, Pune, India.

ORCID-Profile: Gaurav Datta

Zitieren

APA

Datta, G., Verma, S. P., Sinha, S., Tripathi, A. K., Kashyap, R., Mukherji, R., Punuru, R., Saha, A., Middinti, A., Maurya, R., Shukla, A., Kushwaha, R., & Suri, G. (2026). Bridging the Gap: Efficacy of Low‐Dose Emicizumab in Haemophilia A With or Without Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70211

Vancouver

Datta G, Verma SP, Sinha S, Tripathi AK, Kashyap R, Mukherji R, et al. Bridging the Gap: Efficacy of Low‐Dose Emicizumab in Haemophilia A With or Without Inhibitors. Haemophilia. 2026. doi:10.1111/hae.70211

BibTeX
@article{Datta2026,
  author = {Datta, Gaurav and Verma, Shailendra Prasad and Sinha, Swasti and Tripathi, Anil Kumar and Kashyap, Rajesh and Mukherji, Ruchira and Punuru, Raghuveer and Saha, Aritra and Middinti, Akshay and Maurya, Rajkumar and Shukla, Alpika and Kushwaha, Rashmi and Suri, Geeta},
  title = {Bridging the Gap: Efficacy of Low‐Dose Emicizumab in Haemophilia A With or Without Inhibitors},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70211}
}
Kostenlos starten →